KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Change in Inventory (2016 - 2025)

Regeneron Pharmaceuticals has reported Change in Inventory over the past 13 years, most recently at -$2.1 million for Q4 2025.

  • Quarterly results put Change in Inventory at -$2.1 million for Q4 2025, down 101.78% from a year ago — trailing twelve months through Dec 2025 was $275.3 million (down 55.58% YoY), and the annual figure for FY2025 was $275.3 million, down 55.58%.
  • Change in Inventory for Q4 2025 was -$2.1 million at Regeneron Pharmaceuticals, down from $82.6 million in the prior quarter.
  • Over the last five years, Change in Inventory for REGN hit a ceiling of $252.8 million in Q1 2021 and a floor of -$31.3 million in Q2 2021.
  • Median Change in Inventory over the past 5 years was $113.4 million (2021), compared with a mean of $117.9 million.
  • Biggest five-year swings in Change in Inventory: crashed 119.25% in 2021 and later surged 867.09% in 2022.
  • Regeneron Pharmaceuticals' Change in Inventory stood at $163.7 million in 2021, then dropped by 11.85% to $144.3 million in 2022, then crashed by 67.22% to $47.3 million in 2023, then surged by 148.84% to $117.7 million in 2024, then plummeted by 101.78% to -$2.1 million in 2025.
  • The last three reported values for Change in Inventory were -$2.1 million (Q4 2025), $82.6 million (Q3 2025), and $42.5 million (Q2 2025) per Business Quant data.